SCHEMBL6281756

SCHEMBL6281756

CC(C)c1cnc(NC(=O)Nc2ccccc2O)s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 7/20 0.70
CCNE1 P24864 6/20 0.70
CDK5 Q00535 6/20 0.70
SMN1; SMN2 Q16637 2/20 0.56
CCNT1 O60563 1/20 0.56
ALDH1A1 P00352 1/20 0.56
CDK1 P06493 1/20 0.56
CDK4 P11802 1/20 0.56
CCNB1 P14635 1/20 0.56
CCNA2 P20248 1/20 0.56
CCND1 P24385 1/20 0.56
CDK7 P50613 1/20 0.56
CDK9 P50750 1/20 0.56
CCNH P51946 1/20 0.56
MNAT1 P51948 1/20 0.56
CDK5R1 Q15078 1/20 0.56
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
FDPS P14324 1/20 0.44
PSEN1 P49768 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281642 0.86 CDK2 (0.68) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6288089 0.86 CDK2 (0.68) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6288105 0.84 CDK2 (0.69) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6286038 0.84 SMN1; SMN2 (0.65) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6284074 0.82 CDK2 (1.00) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6285449 0.82 CDK2 (0.63) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6282337 0.82 CDK2 (0.62) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6284013 0.81 CDK2 (0.76) CDK2CCNE1CDK5SMN1; SMN2CCNT1
SCHEMBL6282764 0.80 CNR1 (0.63) CDK2CCNE1CDK5NPC1RAB9A
SCHEMBL6282665 0.80 CCNE1 (0.53) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.